Two-Step RT-qPCR for Relative Gene Expression in Human Cells with geNorm-Validated Reference Genes

Three biological replicates per condition, each assayed in technical triplicate on the qPCR plate. Include vehicle and treated arms plus a calibrator (control) condition for ΔΔCq. Load equal RNA mass (500 ng) into each RT reaction. Randomize sample-to-well placement and include inter-plate calibrators if more than one plate is used. Run target and reference assays on the same plate/run when possible to avoid run-to-run variation. Pre-validate primers with a 5-point 10-fold standard curve.

BSL-2 for human cell-derived material until RNA is purified; standard PPE (gloves, coat, eye protection). SYBR Green and intercalating dyes are potential mutagens — handle with gloves and dispose as chemical waste. Keep a nuclease-free RNA workspace separate from PCR-amplicon/post-PCR areas to prevent amplicon carryover contamination; never open post-PCR plates in the prep area. Dispose of sealed plates without reopening.

No-template control (NTC, water instead of cDNA) on every assay to detect contamination/primer-dimer. No-RT control per RNA sample to detect genomic-DNA amplification. Inter-run calibrator (a fixed reference cDNA) on every plate for multi-plate normalization. Positive control: a sample known to express the target. Reference-gene controls: ≥ 2 validated stable genes (geNorm M < 0.5, pairwise V2/3 < 0.15). Vehicle/untreated calibrator defines the 1× baseline for ΔΔCq.

Validated assays give standard-curve efficiency 90–110%, R² ≥ 0.99, single melt peaks, and technical-triplicate Cq SD ≤ 0.25. NTCs should be undetermined or ≥ 35 Cq; no-RT should be ≥ 5 Cq later than +RT. A true 2-fold induction appears as a ≈ 1 Cq decrease after reference normalization. Reference genes should vary < 0.5 Cq across conditions.

• DNase-treated total RNA, RIN ≥ 8, normalized to 500 ng input
• Reverse transcriptase kit with random hexamers + oligo(dT) and RNase inhibitor (e.g., High-Capacity cDNA kit)
• 2× SYBR Green qPCR master mix with ROX reference dye
• Target-gene primer pair, intron-spanning, 100–150 bp amplicon, 0.3 µM final each
• Reference-gene primer pairs (candidates: ACTB, GAPDH, B2M, RPLP0, TBP, HPRT1)
• Nuclease-free water and low-profile 384- or 96-well qPCR plates with optical seals
• No-template control (water) and no-RT control aliquots
• Calibration cDNA dilution series for standard curves

To measure relative expression of a target transcript in human cells across treatments by reverse-transcribing equal RNA mass to cDNA, amplifying with validated, single-amplicon SYBR Green primers, and normalizing to the geometric mean of two stably expressed reference genes selected by geNorm. The objective is MIQE-compliant quantification with documented amplification efficiency (90–110%) and clean melt curves.

1. Normalize all RNA samples to 500 ng in equal volume using nuclease-free water.
2. Assemble RT reactions per kit (e.g., 2 µL 10× buffer, 0.8 µL 25× dNTPs, 2 µL 10× random primers, 1 µL RT, RNase inhibitor, water to 20 µL) for +RT; prepare matched no-RT by omitting enzyme.
3. Run RT: 25 °C 10 min, 37 °C 120 min, 85 °C 5 min, hold 4 °C; dilute cDNA 1:5 in nuclease-free water.
4. Prepare qPCR master mix per target: 5 µL 2× SYBR mix, 0.3 µM each primer, 2 µL diluted cDNA, water to 10 µL.
5. Dispense triplicates; seal; centrifuge plate 1 min at 1,000 × g to remove bubbles.
6. Cycle: 95 °C 10 min; 40 cycles of 95 °C 15 s / 60 °C 60 s; then a 60–95 °C melt-curve ramp.
7. Inspect melt curves for a single peak per assay; reject double peaks or primer-dimer at low Tm.
8. Generate standard curves from a 10-fold dilution series to confirm efficiency 90–110% (slope −3.6 to −3.1, R² ≥ 0.99).
9. Export Cq values; discard technical replicates with > 0.5 Cq spread and re-run if needed.

Independent variable: treatment/condition. Dependent variable: normalized relative expression (fold-change vs calibrator). Controlled variables: RNA input mass (500 ng), cDNA dilution, primer concentration (0.3 µM), master-mix lot, cycling program, plate, and operator. Reference-gene set is held constant once validated. Amplification efficiency is a measured covariate that must fall in 90–110% for valid ΔΔCq.

Treatment will change target mRNA abundance by a biologically meaningful fold-change (e.g., ≥ 2-fold) relative to vehicle, detectable as a reproducible ΔΔCq shift when normalized to the geometric mean of two reference genes whose expression is stable (geNorm M < 0.5) across the conditions tested.

Average technical triplicates per assay. Compute ΔCq = Cq(target) − geometric-mean Cq(reference genes). Compute ΔΔCq = ΔCq(sample) − ΔCq(calibrator). Relative expression = 2^(−ΔΔCq), or use efficiency-corrected Pfaffl when efficiencies differ. Use qbase+, LinRegPCR, or instrument software; set a fixed threshold/baseline across the run. Report MIQE-required metadata (efficiency, RIN, primer sequences).

Late/no amplification: low cDNA or degraded RNA — confirm RIN and re-run RT; check primer efficiency. NTC amplifies: contamination or primer-dimer — use fresh aliquots, redesign primers, lower primer to 0.2 µM. Double melt peak: nonspecific product — raise anneal temp to 62 °C or redesign. High triplicate SD (> 0.5 Cq): pipetting/bubbles — use a master mix, centrifuge plate, calibrate pipettes. Reference genes unstable: re-run geNorm and choose a different reference set.

Perform statistics on log2 fold-change (ΔCq) values, which are approximately normally distributed, not on raw 2^(−ΔΔCq) ratios. Compare two groups by unpaired two-tailed t-test or ≥ 3 groups by one-way ANOVA with Tukey/Dunnett correction (α = 0.05); n = 3 biological replicates. Report mean fold-change with 95% CI. For multiple targets apply Benjamini–Hochberg FDR. With n = 3 and CV ~10% the design detects ~1.5-fold changes at 80% power; increase n for smaller effects.